Fierce Biotech Names Proxygen a “Fierce 15” Biotech Company of 2023

VIENNA, Austria, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising early-stage biotechnology companies in the industry. “It is an incredible honor to be recognized as one of the Fierce 15 biotech companies for 2023,” said Bernd Boidol, Ph.D., chief executive offi

Fierce Life Sciences Events on LinkedIn: The Future of Biotech

Fierce Biotech on LinkedIn: Takeda bets $4B upfront on Nimbus

Mark Federici on LinkedIn: Fierce Biotech Names Proxygen a “Fierce

Fierce Biotech on LinkedIn: Researchers predict Alzheimer's

Fierce Biotech's 2022 Fierce 15

Proxygen LinkedIn

Jacob Perrett on LinkedIn: What does July's biotech funding reveal

Chris Jenkins on LinkedIn: Gene Therapy Finds New Life in an Old Home

Chris Jenkins on LinkedIn: #goteam #ibc #irb

Mark Federici on LinkedIn: Fierce Biotech Names Proxygen a “Fierce

Chris Jenkins on LinkedIn: #goteam #ibc #irb

Chris Jenkins on LinkedIn: Gene Therapy Finds New Life in an Old Home

Fierce Biotech on LinkedIn: Treading where Roche and Sanofi failed

见时知几：2023年Fierce15药企预示着哪些投资趋势- 知乎

Fierce Life Sciences Events on LinkedIn: The Future of Biotech